Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

How we manage Gaucher Disease in the era of choices
Shoshana Revel‐Vilk, Jeff Szer, Atul Mehta, et al.
British Journal of Haematology (2018) Vol. 182, Iss. 4, pp. 467-480
Open Access | Times Cited: 92

Showing 1-25 of 92 citing articles:

The diagnosis and management of Gaucher disease in pediatric patients: Where do we go from here?
Neal J. Weinreb, Özlem Göker-Alpan, Priya S. Kishnani, et al.
Molecular Genetics and Metabolism (2022) Vol. 136, Iss. 1, pp. 4-21
Open Access | Times Cited: 44
Research Progress in the Treatment of Gaucher Disease
晓洁 步
Advances in Clinical Medicine (2025) Vol. 15, Iss. 01, pp. 436-440
Closed Access | Times Cited: 1
Prenatal Delivery of Enzyme Replacement Therapy to Fetuses Affected by Early‐Onset Lysosomal Storage Diseases
Beltran Borges, Emma Canepa, Irene J. Chang, et al.
American Journal of Medical Genetics Part C Seminars in Medical Genetics (2025)
Closed Access | Times Cited: 1
Glucosylsphingosine (lyso-Gb1) as a Biomarker for Monitoring Treated and Untreated Children with Gaucher Disease
Noa Hurvitz, Tama Dinur, Michal Becker‐Cohen, et al.
International Journal of Molecular Sciences (2019) Vol. 20, Iss. 12, pp. 3033-3033
Open Access | Times Cited: 57
Gaucher disease – more than just a rare lipid storage disease
Jaehyeok Roh, Subbaya Subramanian, Neal J. Weinreb, et al.
Journal of Molecular Medicine (2022) Vol. 100, Iss. 4, pp. 499-518
Closed Access | Times Cited: 32
Advancements in Viral Gene Therapy for Gaucher Disease
Akhil M. Kulkarni, Tiffany Chen, Ellen Sidransky, et al.
Genes (2024) Vol. 15, Iss. 3, pp. 364-364
Open Access | Times Cited: 8
Exploring the efficacy and safety of Ambroxol in Gaucher disease: an overview of clinical studies
Feda E. Mohamed, Fatma Al‐Jasmi
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 7
A review on Gaucher disease: therapeutic potential of β-glucocerebrosidase-targeted mRNA/saRNA approach
Shunping Feng, Nino Rcheulishvili, Xiaoming Jiang, et al.
International Journal of Biological Sciences (2024) Vol. 20, Iss. 6, pp. 2111-2129
Open Access | Times Cited: 6
A Feasibility Open-Labeled Clinical Trial Using a Second-Generation Artificial-Intelligence-Based Therapeutic Regimen in Patients with Gaucher Disease Treated with Enzyme Replacement Therapy
Noa Hurvitz, Tama Dinur, Shoshana Revel‐Vilk, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 11, pp. 3325-3325
Open Access | Times Cited: 6
Pharmacologic properties of high-dose ambroxol in four patients with Gaucher disease and myoclonic epilepsy
Yoon-Myung Kim, Mi‐Sun Yum, Sun Hee Heo, et al.
Journal of Medical Genetics (2019) Vol. 57, Iss. 2, pp. 124-131
Open Access | Times Cited: 47
Gaucher Disease Diagnosis Using Lyso-Gb1 on Dry Blood Spot Samples: Time to Change the Paradigm?
Tama Dinur, Peter Bauer, Christian Beetz, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 3, pp. 1627-1627
Open Access | Times Cited: 25
Update of treatment for Gaucher disease
Weijing Kong, Cheng Lu, Yingxue Ding, et al.
European Journal of Pharmacology (2022) Vol. 926, pp. 175023-175023
Closed Access | Times Cited: 23
High-Dose Ambroxol Therapy in Type 1 Gaucher Disease Focusing on Patients with Poor Response to Enzyme Replacement Therapy or Substrate Reduction Therapy
Majdolen Istaiti, Dafna Frydman, Tama Dinur, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 7, pp. 6732-6732
Open Access | Times Cited: 11
Modern Clinical Guidelines for the Management of Patients with Gaucher Disease
И. В. Анисимова, Galina Baydakova, Baranov Aa, et al.
Педиатрическая фармакология (2025) Vol. 21, Iss. 6, pp. 551-568
Open Access
Home Enzyme Replacement Therapy in Gaucher Disease: A Review
Beata Kieć‐Wilk, Paul Guijt, Michaela Dan, et al.
Journal of Clinical Medicine (2025) Vol. 14, Iss. 3, pp. 842-842
Open Access
Evaluation of Lyso-Gb1 as a biomarker for Gaucher disease treatment outcomes using data from the Gaucher Outcome Survey
Ari Zimran, Shoshana Revel‐Vilk, Tama Dinur, et al.
Orphanet Journal of Rare Diseases (2025) Vol. 20, Iss. 1
Open Access
Current and emerging pharmacotherapy for Gaucher disease in pediatric populations
Richard Sam, Emory Ryan, Emily Daykin, et al.
Expert Opinion on Pharmacotherapy (2021) Vol. 22, Iss. 11, pp. 1489-1503
Open Access | Times Cited: 25
Neuroinflammation in Gaucher disease, neuronal ceroid lipofuscinosis, and commonalities with Parkinson’s disease
Laetitia Francelle, Joseph R. Mazzulli
Brain Research (2022) Vol. 1780, pp. 147798-147798
Open Access | Times Cited: 18
Phase 1 Healthy Volunteer Study of AL01211, an Oral, Non‐brain Penetrant Glucosylceramide Synthase Inhibitor, to Treat Fabry Disease and Type 1 Gaucher Disease
M. A. Babcock, Zheng Jian-hong, Jessica Gail Shurr, et al.
Clinical Pharmacology in Drug Development (2024) Vol. 13, Iss. 6, pp. 696-709
Open Access | Times Cited: 3
Neuronopathic Gaucher disease: Rare in the West, common in the East
Özlem Göker-Alpan, Margarita M. Ivanova
Journal of Inherited Metabolic Disease (2024) Vol. 47, Iss. 5, pp. 917-934
Open Access | Times Cited: 3
Long Term Follow-Up of 103 Untreated Adult Patients with Type 1 Gaucher Disease
Tama Dinur, Ari Zimran, Michal Becker‐Cohen, et al.
Journal of Clinical Medicine (2019) Vol. 8, Iss. 10, pp. 1662-1662
Open Access | Times Cited: 26
Hematological manifestations and complications of Gaucher disease
Shoshana Revel‐Vilk, Jeff Szer, Ari Zimran
Expert Review of Hematology (2021) Vol. 14, Iss. 4, pp. 347-354
Closed Access | Times Cited: 21
Pharmacological treatment of pediatric Gaucher disease
Punita Gupta, Gregory M. Pastores
Expert Review of Clinical Pharmacology (2018) Vol. 11, Iss. 12, pp. 1183-1194
Closed Access | Times Cited: 26
Impact of Long-Term Enzyme Replacement Therapy on Glucosylsphingosine (Lyso-Gb1) Values in Patients with Type 1 Gaucher Disease: Statistical Models for Comparing Three Enzymatic Formulations
Tama Dinur, Ulrike Grittner, Shoshana Revel‐Vilk, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 14, pp. 7699-7699
Open Access | Times Cited: 18
Glycosphingolipids
Elena Chiricozzi, Massimo Aureli, Laura Mauri, et al.
Advances in experimental medicine and biology (2021), pp. 61-102
Closed Access | Times Cited: 16
Page 1 - Next Page

Scroll to top